Medical and Economic Evaluation for Intermediate-risk Prostate Cancer (GETUGP05)

This is an interventional treatment trial for Prostate Cancer focused on measuring Prostate, external beam radiotherapy, brachytherapy boost, economical evaluation Read More

Inclusion Criteria:

• age between 18 and 80 years;
• life expectancy of greater than 10 years;
• prostate adenocarcinoma histologically proven;
• prostate cancer has to be of intermediate-risk based on at least one of the three following criteria: PSA between 10 ng/ml and 20 ng/ml, and/or a Gleason score of 7 and/or a T2B. Karnofsky performance status ≥ 60% and consequently performance status ECOG 0-2.
• the patient has to be the beneficiary of the social security system (order n° 2006-477 from April 26th 2006);
• the signed consent form.

Exclusion Criteria:

• PSA level > 20;
• Gleason > 7;
• clinical T3A or T3B or MRI (a simple suspicion/ doubt on the MRI regarding the T3A won't be an exclusion criterion);
• prostate volume > 60 cc;
• pelvic lymph nodes involvement at dissection or imaging (ADP > 1.5 cm);
• concurrent hormone therapy;
• the presence of distant metastasis (M1);
• history of abdominal or pelvic irradiation;
• history of prostate resection in the previous 6 months and/or not allowing the implantation of markers;
• history of uncontrolled cancer and/or treated since less than 5 years (excepting the basal-cell carcinoma);
• urinary discomfort with an IPSS (International Prostate Symptom Score) > 15 (without alpha-blocking);
• inflammatory bowel disorder such as ulcerative colitis or the Crohn's disease;
• other undergoing study that may interfere with the present study;
• patient under legal protection measure.